NCT06903026 PRevalence Of Transient Global Amnesia in Obstructive Sleep Apnea Syndrome
| NCT ID | NCT06903026 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Transient Global Amnesia |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2023-03-17 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2023-03-17 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Amnesic stroke is an amnestic syndrome lasting less than 24 hours characterized by the occurrence of anterograde amnesia often associated with retrograde amnesia, the pathophysiology of which is still poorly understood at present. A recent study on a small sample size (N=29) highlighted an association between obstructive sleep apnea syndrome and amnesic stroke. Our study seeks to confirm or refute these results on a larger cohort (N=200-250). A better understanding of the pathophysiological processes involved would open up new therapeutic avenues.
Eligibility Criteria
Inclusion Criteria: * Adult patients seen for consultation in the Neuropsychology Department of Strasbourg University Hospital between March 1, 2015 and December 31, 2021 following an episode of amnestic stroke meeting the Hodges and Warlow criteria: * The stroke must have been documented and reported by a competent witness present during the stroke. * Anterograde amnesia during the stroke. * Absence of vigilance, personality, and cognitive disorders other than memory disorders (aphasia, apraxia, etc.). * Absence of focal neurological symptoms during the episode and its aftermath. * Absence of epileptic manifestations. * Resolution of the episode in less than 24 hours. * Exclusion of patients with a history of recent head trauma or active epilepsy (undergoing regular treatment or having experienced a seizure in the last 2 years). * Subjects who have not expressed opposition to the reuse of their data for scientific research purposes. Exclusion Criteria: * Patients who have expressed opposition to the retrospective reuse of their data for scientific research purposes. * Patients with active epilepsy * Patients with recent head trauma * Patients with an MMS \< or equal to 25 * Subject under guardianship or curatorship * Subject under judicial protection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06903026 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transient Global Amnesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06903026 currently recruiting?
Yes, NCT06903026 is actively recruiting participants. Contact the research team at benjamin.cretin@chru-trasbourg.fr for enrollment information.
Where is the NCT06903026 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT06903026 clinical trial?
NCT06903026 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 250 participants.